Lynette I Ochola-Oyier
Overview
Explore the profile of Lynette I Ochola-Oyier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lugano D, Kutima B, Kimani M, Sigilai A, Gitonga J, Karani A, et al.
BMC Infect Dis
. 2024 Dec;
24(1):1474.
PMID: 39732637
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing...
2.
Martinez-Vega R, Ishengoma D, Gosling R, Rosenthal P, Dondorp A, Barnes K, et al.
Lancet
. 2024 Dec;
405(10472):7-10.
PMID: 39674185
No abstract available.
3.
Kagucia E, Ziraba A, Nyagwange J, Kutima B, Kimani M, Akech D, et al.
Influenza Other Respir Viruses
. 2023 Sep;
17(9):e13173.
PMID: 37752065
Background: We sought to estimate SARS-CoV-2 antibody seroprevalence within representative samples of the Kenyan population during the third year of the COVID-19 pandemic and the second year of COVID-19 vaccine...
4.
Etyang A, Adetifa I, Omore R, Misore T, Ziraba A, Ngoda M, et al.
PLOS Glob Public Health
. 2023 Mar;
2(8):e0000883.
PMID: 36962821
Background: Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population....
5.
Ojal J, Brand S, Were V, Okiro E, Kombe I, Mburu C, et al.
Wellcome Open Res
. 2022 Dec;
6:127.
PMID: 36187498
Policymakers in Africa need robust estimates of the current and future spread of SARS-CoV-2. We used national surveillance PCR test, serological survey and mobility data to develop and fit a...
6.
Nyagwange J, Kutima B, Mwai K, Karanja H, Gitonga J, Mugo D, et al.
Int J Infect Dis
. 2022 Dec;
127:11-16.
PMID: 36476349
Objectives: Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing...
7.
Tegally H, San J, Cotten M, Moir M, Tegomoh B, Mboowa G, et al.
Science
. 2022 Sep;
378(6615):eabq5358.
PMID: 36108049
Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing in Africa over the past year has led to a major increase in the number of sequences that have been...
8.
Orangi S, Ojal J, Brand S, Orlendo C, Kairu A, Aziza R, et al.
BMJ Glob Health
. 2022 Aug;
7(8).
PMID: 35914832
Background: A few studies have assessed the epidemiological impact and the cost-effectiveness of COVID-19 vaccines in settings where most of the population had been exposed to SARS-CoV-2 infection. Methods: We...
9.
Nyagwange J, Kutima B, Mwai K, Karanja H, Gitonga J, Mugo D, et al.
J Clin Virol
. 2022 Jan;
146:105061.
PMID: 34973474
Many SARS-CoV-2 antibody detection assays have been developed but their differential performance is not well described. In this study we compared an in-house (KWTRP) ELISA which has been used extensively...
10.
Kagucia E, Gitonga J, Kalu C, Ochomo E, Ochieng B, Kuya N, et al.
Open Forum Infect Dis
. 2021 Oct;
8(7):ofab314.
PMID: 34660838
In October 2020, anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) G seroprevalence among truck drivers and their assistants (TDA) in Kenya was 42.3%, higher than among healthcare workers and blood...